Pharmacoepidemiology, Fourth Edition

Content: Chapter 1 What is Pharmacoepidemiology? (pages 1–15): Brian L. Strom Chapter 2 Study Designs Available for Pharmacoepidemiology Studies (pages 17–28): Brian L. Strom Chapter 3 Sample Size Considerations for Pharmacoepidemiology Studies (pages 29–36): Brian L. Strom Chapter 4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies (pages 37–57): David A. Henry, Patricia McGettigan, Anne Tonkin and Sean Hennessy Chapter 5 When Should One Perform Pharmacoepidemiology Studies? (pages 59–66): Brian L. Strom Chapter 6 A View from Academia (pages 67–76): Robert M. Califf and Leanne K. Madre Chapter 7 A View from Industry (pages 77–101): Robert F. Reynolds, Dale B. Glasser and Gretchen S. Dieck Chapter 8 A View from Regulatory Agencies (pages 103–130): Peter Arlett, Jane Moseley and Paul J. Seligman Chapter 9 Spontaneous Reporting in the United States (pages 131–159): Syed Rizwanuddin Ahmad, Roger A. Goetsch and Norman S. Marks Chapter 10 Global Drug Surveillance: The WHO Programme for International Drug Monitoring (pages 161–183): I. Ralph Edwards, Sten Olsson, Marie Lindquist and Bruce Hugman Chapter 11 Case–Control Surveillance (pages 185–202): Lynn Rosenberg, Patricia F. Coogan and Julie R. Palmer Chapter 12 Prescription?Event Monitoring (pages 203–216): Saad A. W. Shakir Chapter 13 Overview of Automated Databases in Pharmacoepidemiology (pages 217–222): Brian L. Strom Chapter 14 Group Health Cooperative (pages 223–239): Kathleen W. Saunders, Robert L. Davis and Andy Stergachis Chapter 15 Kaiser Permanente Medical Care Program (pages 241–259): Joe V. Selby, David H. Smith, Eric S. Johnson, Marsha A. Raebel, Gary D. Friedman and Bentson H. McFarland Chapter 16 The HMO Research Network (pages 261–269): K. Arnold Chan, Robert L. Davis, Margaret J. Gunter, Jerry H. Gurwitz, Lisa J. Herrinton, Winnie W. Nelson, Marsha A. Raebel, Douglas W. Roblin, David H. Smith and Richard Platt Chapter 17 UnitedHealth Group (pages 271–280): Deborah Shatin, Nigel S. B. Rawson and Andy Stergachis Chapter 18 Medicaid Databases (pages 281–294): Sean Hennessy, Jeffrey L. Carson, Wayne A. Ray and Brian L. Strom Chapter 19 Health Services Databases in Saskatchewan (pages 295–310): Winanne Downey, Maryrose Stang, Patricia Beck, William Osei and James L. Nichol Chapter 20 Automated Pharmacy Record Linkage in The Netherlands (pages 311–322): Hubert G. Leufkens and John Urquhart Chapter 21 The Tayside Medicines Monitoring Unit (MEMO) (pages 323–336): Li Wei, John Parkinson and Thomas M. MacDonald Chapter 22 The UK General Practice Research Database (pages 337–346): Joel M. Gelfand, David J. Margolis and Hassy Dattani Chapter 23 Other Approaches to Pharmacoepidemiology Studies (pages 347–362): Brian L. Strom Chapter 24 How Should One Perform Pharmacoepidemiology Studies? Choosing Among the Available Alternatives (pages 363–374): Brian L. Strom Chapter 25 National Medicinal Drug Policies: Their Relationship to Pharmacoepidemiology (pages 375–390): Suzanne Hill and David A. Henry Chapter 26 Premarketing Applications of Pharmacoepidemiology (pages 391–400): Harry A. Guess Chapter 27 Studies of Drug Utilization (pages 401–417): David Lee and Ulf Bergman Chapter 28 Evaluating and Improving Physician Prescribing (pages 419–437): Sumit R. Majumdar, Helene Levens Lipton and Stephen B. Soumerai Chapter 29 Drug Utilization Review (pages 439–453): Sean Hennessy, Stephen B. Soumerai, Helene Levens Lipton and Brian L. Strom Chapter 30 Special Methodological Issues in Pharmacoepidemiology Studies of Vaccine Safety (pages 455–485): Robert T. Chen, Robert L. Davis and Philip H. Rhodes Chapter 31 Pharmacoepidemiologic Studies of Devices (pages 487–500): Roselie A. Bright Chapter 32 Studies of Drug?Induced Birth Defects (pages 501–514): Allen A. Mitchell Chapter 33 Pharmacoepidemiology and Risk Management (pages 515–530): David J. Graham, Andrew D. Mosholder, Kate Gelperin and Mark I. Avigan Chapter 34 The Use of Pharmacoepidemiology to Study Medication Errors (pages 531–538): Rainu Kaushal and David W. Bates Chapter 35 Hospital Pharmacoepidemiology (pages 539–553): Brian L. Strom and Rita Schinnar Chapter 36 Determining Causation from Case Reports (pages 555–570): Judith K. Jones Chapter 37 Molecular Pharmacoepidemiology (pages 571–586): Stephen E. Kimmel, Hubert G. Leufkens and Timothy R. Rebbeck Chapter 38 Bioethical Issues in Pharmacoepidemiologic Research (pages 587–598): David Casarett, Jason Karlawish, Elizabeth Andrews and Arthur Caplan Chapter 39 The Use of Randomized Controlled Trials for Pharmacoepidemiology Studies (pages 599–610): Samuel M. Lesko and Allen A. Mitchell Chapter 40 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects (pages 611–628): Brian L. Strom and Kenneth L. Melmon (the late) Chapter 41 Pharmacoeconomics: Economic Evaluation of Pharmaceuticals (pages 629–652): Kevin A. Schulman, Henry A. Glick and Daniel Polsky Chapter 42 Using Quality?of?Life Measurements in Pharmacoepidemiologic Research (pages 653–663): Holger Schunemann, Gordon H. Guyatt and Roman Jaeschke Chapter 43 N?of?1 Randomized Clinical Trials in Pharmacoepidemiology (pages 665–680): Gordon H. Guyatt, Roman Jaeschke and Robin Roberts Chapter 44 The Use of Meta?analysis in Pharmacoepidemiology (pages 681–707): Jesse A. Berlin and Carin J. Kim Chapter 45 Validity of Pharmacoepidemiologic Drug and Diagnosis Data (pages 709–765): Suzanne L. West, Brian L. Strom and Charles Poole Chapter 46 Variable Compliance and Persistence with Prescribed Drug Dosing Regimens: Implications for Benefits, Risks, and Economics of Pharmacotherapy (pages 767–789): John Urquhart Chapter 47 Bias and Confounding in Pharmacoepidemiology (pages 791–809): Ilona Csizmadi, Jean?Paul Collet and Jean?Francois Boivin Chapter 48 Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis (pages 811–829): Samy Suissa Chapter 49 The Future of Pharmacoepidemiology (pages 831–839): Brian L. Strom and Sean Hennessy

The fourth edition of Pharmacoepidemiology is an outstanding and fully comprehensive textbook, which will be an essential resource for all interested in the field—in academia, in regulatory agencies, in industry and in the law. Brian Strom's classic textbook continues both to reflect the increased maturation of pharmacoepedemiology and to help shape it's direction.

Reviews of previous editions of his celebrated textbook include:

"The book is essential reading for anyone interested in pharmacoepidemiology."

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

"...an excellent textbook and a comprehensive reference which belongs in the library of every pharmaceutical manufacturer and regulator."

EUROPEAN JOURNAL OF PUBLIC HEALTH

The fourth edition of Pharmacoepidemiology is an outstanding and fully comprehensive textbook, which will be an essential resource for all interested in the field--in academia, in regulatory agencies, in industry and in the law. Brian Strom's classic textbook continues both to reflect the increased maturation of pharmacoepedemiology and to help shape it's direction. Reviews of previous editions of his celebrated textbook include: "The book is essential reading for anyone interested in pharmacoepidemiology." INTERNATIONAL JOURNAL OF EPIDEMIOLOGY "...an excellent textbook and a comprehensive reference which belongs in the library of every pharmaceutical manufacturer and regulator." EUROPEAN JOURNAL OF PUBLIC HEALTH "Appropriate and valid pharmacoepidemiology methods are central to evaluating the safety and effectiveness of medicines and their use. Brian Strom's book, now in its fourth edition, is the comprehensive text for such evaluations. It provides methods, details of potential data sources, and information about evaluating the results and drawing conclusions. The successful layout and easy to read style is retained while the topics have been thoroughly revised to document the developments in the field."--BOOK JACKET